Top Markets
#1 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.51%
#2 Fake World Assets Fake World Assets +18.28%
#3 Status Status +17.90%
#4 GoPlus Security GoPlus Security +11.51%
#5 Ontology Gas Ontology Gas +10.01%
#6 Bedrock Bedrock +7.70%
#7 DMT-NAT DMT-NAT +7.61%
#8 Cap Cap +6.73%
#9 Provenance Blockchain Provenance Blockchain +6.73%
#10 Janction Janction +5.45%
Coin of the day
FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock)
Settings
Language
ENGLISH
Currency
USD
Theme
Renalytix Plc Renalytix Plc

Renalytix Plc

RNLX
Rank in Stocks #33998
Renalytix Plc, established in New York in 2018 and known as Renalytix AI plc... Renalytix Plc, established in New York in 2018 and known as Renalytix AI plc until its name change in June 2021, focuses on creating artificial intelligence-driven in vitro diagnostic tools for kidney ailments. Its primary product, KidneyIntelX, is an advanced diagnostic system that utilizes an AI-powered algorithm. This algorithm integrates multiple data sources, including scientifically validated blood markers, genetic predispositions, and individual patient information from electronic health records, to produce a distinct risk score for kidney disease. The company's technology is applied in various areas: identifying and predicting the course of kidney disease, informing clinical treatment, selecting patients for pharmaceutical trials, and discovering new therapeutic targets. Renalytix has formed several strategic collaborations, such as licensing agreements with Mount Sinai Health System for AI-assisted kidney disease diagnosis, with Joslin Diabetes Center, Inc. for developing biomarker-based kidney disease prediction products, and with Kantaro Biosciences LLC for laboratory tests to detect SARS-CoV-2 antibodies. Furthermore, it has partnered with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to introduce an innovative clinical care model aimed at improving kidney health outcomes and preventing disease advancement and failure in vulnerable populations.
Share Price
$0.1502
Last synced: 2024-11-04
Market Cap
$6.43M
Change (1 day)
-5.45%
Change (1 year)
0.00%
Country
US
Trade Renalytix Plc (RNLX)

Category

Healthcare
Operating Margin for Renalytix Plc (RNLX)
Operating Margin as of August 2026 TTM: -1,293.49%
According to Renalytix Plc latest financial reports and stock price the company's current Operating Margin (TTM) is -1,293.49%. At the end of 2023 the company had an Operating Margin of -1,244.64%.
Operating Margin history for Renalytix Plc from 2018 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
2026 (TTM) -1,293.49% 0.00%
2024 -1,293.49% 3.92%
2023 -1,244.64% -35.57%
2022 -1,931.72% -11.68%
2021 -2,187.19% 0.00%
2020 0.00% 0.00%
2019 0.00% 0.00%
2018 0.00% 0.00%
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
GE HealthCare Technologies Inc. GE HealthCare Technologies Inc.
GE HealthCare Technologies Inc.
GEHC.US
12.70% -100.01%
US
Pro Medicus Limited Pro Medicus Limited
Pro Medicus Limited
PME.AX
74.17% -100.06%
AU
BrightSpring Health Services, Inc. Common Stock BrightSpring Health Services, Inc. Common Stock
BrightSpring Health Services, Inc. Common Stock
BTSG.US
3.33% -100.00%
US
Tempus AI, Inc. Tempus AI, Inc.
Tempus AI, Inc.
TEM.US
-19.76% -99.98%
US
Signify Health, Inc. Signify Health, Inc.
Signify Health, Inc.
SGFY.US
0.00% -
US
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.